
Dewanda A. Samuel
Examiner (ID: 3769, Phone: (571)270-1213 , Office: P/2464 )
| Most Active Art Unit | 2464 |
| Art Unit(s) | 2616, 2416, 2464 |
| Total Applications | 590 |
| Issued Applications | 495 |
| Pending Applications | 2 |
| Abandoned Applications | 96 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16283751
[patent_doc_number] => 20200277353
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => THERAPEUTIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/877035
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877035
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877035 | Therapeutic agents | May 17, 2020 | Issued |
Array
(
[id] => 16557468
[patent_doc_number] => 20210002616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => DEVELOPMENT OF SUPERIOR CHIMERISM BY hiPSC ENGINEERING AND EMBRYO AGGREGATION
[patent_app_type] => utility
[patent_app_number] => 16/877294
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23755
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877294
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877294 | Development of superior chimerism by hiPSC engineering and embryo aggregation | May 17, 2020 | Issued |
Array
(
[id] => 18747077
[patent_doc_number] => 11806368
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Stem cell subpopulations with differential GSTT1 expression or genotype
[patent_app_type] => utility
[patent_app_number] => 16/875486
[patent_app_country] => US
[patent_app_date] => 2020-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 54
[patent_no_of_words] => 25404
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 207
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875486
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/875486 | Stem cell subpopulations with differential GSTT1 expression or genotype | May 14, 2020 | Issued |
Array
(
[id] => 16663238
[patent_doc_number] => 10932455
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-02
[patent_title] => Non-human animals expressing humanized CD3 complex
[patent_app_type] => utility
[patent_app_number] => 16/872226
[patent_app_country] => US
[patent_app_date] => 2020-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 17
[patent_no_of_words] => 18200
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872226
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/872226 | Non-human animals expressing humanized CD3 complex | May 10, 2020 | Issued |
Array
(
[id] => 17193336
[patent_doc_number] => 11162079
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Blood type O Rh-hypo-immunogenic pluripotent cells
[patent_app_type] => utility
[patent_app_number] => 16/870959
[patent_app_country] => US
[patent_app_date] => 2020-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 21078
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16870959
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/870959 | Blood type O Rh-hypo-immunogenic pluripotent cells | May 8, 2020 | Issued |
Array
(
[id] => 16358397
[patent_doc_number] => 20200315148
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => METHOD FOR PRODUCING CHIMERIC ANIMAL
[patent_app_type] => utility
[patent_app_number] => 16/857855
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16615
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857855
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/857855 | Method for producing chimeric animal | Apr 23, 2020 | Issued |
Array
(
[id] => 16206550
[patent_doc_number] => 20200239540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)
[patent_app_type] => utility
[patent_app_number] => 16/851649
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851649
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/851649 | CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S) | Apr 16, 2020 | Abandoned |
Array
(
[id] => 16206549
[patent_doc_number] => 20200239539
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)
[patent_app_type] => utility
[patent_app_number] => 16/851634
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/851634 | CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S) | Apr 16, 2020 | Abandoned |
Array
(
[id] => 19622913
[patent_doc_number] => 12161705
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Chimeric antigen receptor specific for tumor cells
[patent_app_type] => utility
[patent_app_number] => 16/833707
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 10632
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833707
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833707 | Chimeric antigen receptor specific for tumor cells | Mar 29, 2020 | Issued |
Array
(
[id] => 16296356
[patent_doc_number] => 20200282079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => METHODS AND COMPOSITIONS FOR ENGINEERING IMMUNITY
[patent_app_type] => utility
[patent_app_number] => 16/834481
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16834481
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/834481 | Methods and compositions for engineering immunity | Mar 29, 2020 | Issued |
Array
(
[id] => 18590416
[patent_doc_number] => 11739300
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => RNA preparations comprising purified modified RNA for reprogramming cells
[patent_app_type] => utility
[patent_app_number] => 16/827098
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 53
[patent_no_of_words] => 47055
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827098
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/827098 | RNA preparations comprising purified modified RNA for reprogramming cells | Mar 22, 2020 | Issued |
Array
(
[id] => 17609854
[patent_doc_number] => 20220152133
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => MODIFIED ADENOVIRUS AND MEDICINE COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/439184
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7524
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439184
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439184 | Modified adenovirus and medicine comprising same | Mar 18, 2020 | Issued |
Array
(
[id] => 16309944
[patent_doc_number] => 20200288682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => Method of Producing a Novel Animal Model for Tauopathies
[patent_app_type] => utility
[patent_app_number] => 16/805203
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805203
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/805203 | Method of producing a novel animal model for tauopathies | Feb 27, 2020 | Issued |
Array
(
[id] => 16191084
[patent_doc_number] => 20200231933
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => HUMAN PLURIPOTENT STEM CELL DERIVED ENDOCARDIAL ENDOTHELIUM
[patent_app_type] => utility
[patent_app_number] => 16/801559
[patent_app_country] => US
[patent_app_date] => 2020-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30756
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801559
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/801559 | Human pluripotent stem cell derived endocardial endothelium | Feb 25, 2020 | Issued |
Array
(
[id] => 18302159
[patent_doc_number] => 11624052
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-11
[patent_title] => Functional sex-reversal of decapod crustacean females
[patent_app_type] => utility
[patent_app_number] => 16/798883
[patent_app_country] => US
[patent_app_date] => 2020-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 11
[patent_no_of_words] => 9693
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798883
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798883 | Functional sex-reversal of decapod crustacean females | Feb 23, 2020 | Issued |
Array
(
[id] => 19105811
[patent_doc_number] => 11958892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Use of ICOS-based cars to enhance antitumor activity and car persistence
[patent_app_type] => utility
[patent_app_number] => 16/792771
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 21
[patent_no_of_words] => 29181
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/792771 | Use of ICOS-based cars to enhance antitumor activity and car persistence | Feb 16, 2020 | Issued |
Array
(
[id] => 18604905
[patent_doc_number] => 11746360
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Eukaryotic cell transfection systems and related methods
[patent_app_type] => utility
[patent_app_number] => 16/788303
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 16227
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788303
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/788303 | Eukaryotic cell transfection systems and related methods | Feb 10, 2020 | Issued |
Array
(
[id] => 16012791
[patent_doc_number] => 20200181238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => TRANSDUCED T CELLS EXPRESSING HUMAN SSTR2 AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/787539
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15040
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787539
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787539 | Transduced T cells expressing human SSTR2 and application thereof | Feb 10, 2020 | Issued |
Array
(
[id] => 16267315
[patent_doc_number] => 20200268802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING AN IMMUNE RESPONSE-STIMULATING CYTOKINE TO ATTRACT AND/OR ACTIVATE IMMUNE CELLS
[patent_app_type] => utility
[patent_app_number] => 16/774495
[patent_app_country] => US
[patent_app_date] => 2020-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17154
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16774495
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/774495 | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | Jan 27, 2020 | Issued |
Array
(
[id] => 16191083
[patent_doc_number] => 20200231932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => DORSALLY-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 16/750975
[patent_app_country] => US
[patent_app_date] => 2020-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750975
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/750975 | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells | Jan 22, 2020 | Issued |